Astellas Pharma Future Growth
Future criteria checks 1/6
Astellas Pharma's revenue is forecast to decline at 3.6% per annum while its annual earnings are expected to grow at 7.6% per year. EPS is expected to grow by 7.6% per annum. Return on equity is forecast to be 12.2% in 3 years.
Key information
7.6%
Earnings growth rate
7.61%
EPS growth rate
| Pharmaceuticals earnings growth | 9.0% |
| Revenue growth rate | -3.6% |
| Future return on equity | 12.23% |
| Analyst coverage | Good |
| Last updated | 02 Oct 2025 |
Recent future growth updates
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 01
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 29Astellas Pharma Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
Feb 07Recent updates
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Sep 19Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 01Astellas Pharma (TSE:4503) Is Increasing Its Dividend To ¥39.00
Jul 24Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year
Jul 10Astellas Pharma Inc.'s (TSE:4503) P/E Is On The Mark
Jun 20Statutory Profit Doesn't Reflect How Good Astellas Pharma's (TSE:4503) Earnings Are
May 08Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 29These 4 Measures Indicate That Astellas Pharma (TSE:4503) Is Using Debt Reasonably Well
Mar 13Astellas Pharma (TSE:4503) Is Due To Pay A Dividend Of ¥37.00
Feb 15Astellas Pharma Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
Feb 07Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00
Feb 01Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00
Jan 17Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00
Jan 03
Strategic Brands XTANDI And PADCEV Ignite Growth And Boost Margins In Pharma Innovator
Strategic brand growth and expanded product indications are driving revenue and upward revisions in forecasts, particularly in key markets like the U.S.Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00
Dec 04Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
Nov 06Astellas Pharma Inc. (TSE:4503) Just Released Its Half-Yearly Earnings: Here's What Analysts Think
Nov 01Astellas Pharma Inc.'s (TSE:4503) Earnings Haven't Escaped The Attention Of Investors
Oct 15Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2028 | 1,893,024 | 204,376 | 414,364 | 494,923 | 13 |
| 3/31/2027 | 2,083,488 | 224,777 | 359,451 | 435,633 | 14 |
| 3/31/2026 | 2,002,304 | 158,512 | 272,688 | 350,141 | 14 |
| 6/30/2025 | 1,944,993 | 81,566 | 189,328 | 236,749 | N/A |
| 3/31/2025 | 1,912,323 | 50,747 | 138,341 | 194,512 | N/A |
| 12/31/2024 | 1,867,631 | -57,427 | 101,141 | 165,416 | N/A |
| 9/30/2024 | 1,772,155 | 54,746 | 125,654 | 200,804 | N/A |
| 6/30/2024 | 1,701,806 | 21,519 | 92,795 | 172,877 | N/A |
| 3/31/2024 | 1,603,672 | 17,045 | 100,981 | 172,475 | N/A |
| 12/31/2023 | 1,543,324 | 4,198 | 136,404 | 216,089 | N/A |
| 9/30/2023 | 1,523,572 | 38,090 | 151,562 | 236,992 | N/A |
| 6/30/2023 | 1,511,818 | 107,031 | 205,852 | 291,133 | N/A |
| 3/31/2023 | 1,518,619 | 98,714 | 239,438 | 327,767 | N/A |
| 12/31/2022 | 1,468,235 | 136,430 | 183,399 | 260,759 | N/A |
| 9/30/2022 | 1,406,682 | 148,911 | 214,107 | 257,916 | N/A |
| 6/30/2022 | 1,351,811 | 118,211 | 215,849 | 266,193 | N/A |
| 3/31/2022 | 1,296,163 | 124,086 | 205,277 | 257,444 | N/A |
| 12/31/2021 | 1,300,914 | 120,167 | 236,959 | 290,559 | N/A |
| 9/30/2021 | 1,285,714 | 119,360 | 248,993 | 331,268 | N/A |
| 6/30/2021 | 1,268,702 | 100,863 | 261,235 | 325,326 | N/A |
| 3/31/2021 | 1,249,528 | 120,589 | 229,402 | 306,843 | N/A |
| 12/31/2020 | 1,253,215 | 138,307 | 196,679 | 276,851 | N/A |
| 9/30/2020 | 1,265,853 | 139,722 | 146,751 | 235,299 | N/A |
| 6/30/2020 | 1,273,678 | 187,306 | 135,534 | 236,186 | N/A |
| 3/31/2020 | 1,300,843 | 195,411 | 144,110 | 221,998 | N/A |
| 12/31/2019 | 1,289,855 | 220,751 | 151,021 | 225,239 | N/A |
| 9/30/2019 | 1,309,722 | 246,925 | 182,693 | 248,203 | N/A |
| 6/30/2019 | 1,311,397 | 226,224 | 176,251 | 228,863 | N/A |
| 3/31/2019 | 1,306,348 | 222,265 | N/A | 258,630 | N/A |
| 12/31/2018 | 1,305,901 | 213,600 | N/A | 300,955 | N/A |
| 9/30/2018 | 1,307,658 | 186,429 | N/A | 309,442 | N/A |
| 6/30/2018 | 1,306,830 | 176,770 | N/A | 290,301 | N/A |
| 3/31/2018 | 1,300,316 | 164,679 | N/A | 312,614 | N/A |
| 12/31/2017 | 1,305,521 | 182,515 | N/A | 264,549 | N/A |
| 9/30/2017 | 1,299,746 | 185,754 | N/A | 260,795 | N/A |
| 6/30/2017 | 1,296,484 | 194,556 | N/A | 276,954 | N/A |
| 3/31/2017 | 1,311,665 | 218,701 | N/A | 235,612 | N/A |
| 12/31/2016 | 1,312,627 | 207,940 | N/A | 325,459 | N/A |
| 9/30/2016 | 1,336,878 | 205,818 | N/A | 308,800 | N/A |
| 6/30/2016 | 1,366,799 | 215,678 | N/A | 302,245 | N/A |
| 3/31/2016 | 1,372,706 | 193,687 | N/A | 313,737 | N/A |
| 12/31/2015 | 1,360,153 | 185,659 | N/A | 207,806 | N/A |
| 9/30/2015 | 1,340,307 | 168,805 | N/A | 182,815 | N/A |
| 6/30/2015 | 1,295,761 | 144,617 | N/A | 156,675 | N/A |
| 3/31/2015 | 1,247,259 | 135,856 | N/A | 187,686 | N/A |
| 12/31/2014 | 1,205,276 | 124,154 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4503's forecast earnings growth (7.6% per year) is above the savings rate (0.5%).
Earnings vs Market: 4503's earnings (7.6% per year) are forecast to grow slower than the JP market (8.2% per year).
High Growth Earnings: 4503's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4503's revenue is expected to decline over the next 3 years (-3.6% per year).
High Growth Revenue: 4503's revenue is forecast to decline over the next 3 years (-3.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4503's Return on Equity is forecast to be low in 3 years time (12.2%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 14:16 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Astellas Pharma Inc. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hazim Bahari | CFRA Equity Research |